fda declaratory order semaglutide shortage resolved Novo's Wegovy and Ozempic removed from US list, compounders on notice 📢 FDA has determined the

K., Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation

Early in vivo electrophysiological recordings showed that juxtacellular application of the active fragment of GLP-1, GLP-1 (736) amide induces an increase and then a decrease of firing activity in the hippocampal CA1 neurons

Notably, although gallbladder disorders frequently manifest, advanced gastrointestinal complications such as intestinal obstruction and periprocedural aspiration, and emergent concerns regarding suicidality and ocular problems require further longitudinal studies to refine the usage guidelines for GLP-1 RAs in susceptible populations

Topline results from the KaiNETIC programme are expected in 2028

Wegovy (a higher dose of semaglutide) is approved for use in Australia to treat obesity but its not yet available

Results Preliminary analyses (first measurement n=50